Your browser doesn't support javascript.
loading
PD1 inhibits PKCθ-dependent phosphorylation of cytoskeleton-related proteins and immune synapse formation.
Chmiest, Daniela; Podavini, Silvia; Ioannidou, Kalliopi; Vallois, David; Décaillet, Chantal; Gonzalez, Montserrat; Quadroni, Manfredo; Blackney, Kevin; Schairer, Rebekka; de Leval, Laurence; Thome, Margot.
Afiliação
  • Chmiest D; Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
  • Podavini S; Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
  • Ioannidou K; Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Vallois D; Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Décaillet C; Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
  • Gonzalez M; Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
  • Quadroni M; Protein Analysis Facility, University of Lausanne, Lausanne, Switzerland.
  • Blackney K; Flow Cytometry Facility, Department of Formation and Research, University of Lausanne, Epalinges, Switzerland.
  • Schairer R; Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology, and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
  • de Leval L; Department of Laboratory Medicine and Pathology, Institute of Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Thome M; Department of Immunobiology, University of Lausanne, Epalinges, Switzerland.
Blood Adv ; 8(11): 2908-2923, 2024 Jun 11.
Article em En | MEDLINE | ID: mdl-38513140
ABSTRACT
ABSTRACT The inhibitory surface receptor programmed cell death protein 1 (PD1) is a major target for antibody-based cancer immunotherapies. Nevertheless, a substantial number of patients fail to respond to the treatment or experience adverse effects. An improved understanding of intracellular pathways targeted by PD1 is thus needed to develop better predictive and prognostic biomarkers. Here, via unbiased phosphoproteome analysis of primary humancells, we demonstrate that PD1 triggering inhibited the phosphorylation and physical association with protein kinase Cθ (PKCθ) of a variety of cytoskeleton-related proteins. PD1 blocked activation and recruitment of PKCθ to the forming immune synapse (IS) in a Src homology-2 domain-containing phosphatase-1/2 (SHP1/SHP2)-dependent manner. Consequently, PD1 engagement led to impaired synaptic phosphorylation of cytoskeleton-related proteins and formation of smaller IS. T-cell receptor induced phosphorylation of the PKCθ substrate and binding partner vimentin was long-lasting and it could be durably inhibited by PD1 triggering. Vimentin phosphorylation in intratumoral T cells also inversely correlated with the levels of the PD1 ligand, PDL1, in human lung carcinoma. Thus, PKCθ and its substrate vimentin represent important targets of PD1-mediated T-cell inhibition, and low levels of vimentin phosphorylation may serve as a biomarker for the activation of the PD1 pathway.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sinapses Imunológicas / Receptor de Morte Celular Programada 1 / Proteína Quinase C-theta Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Sinapses Imunológicas / Receptor de Morte Celular Programada 1 / Proteína Quinase C-theta Limite: Humans Idioma: En Revista: Blood Adv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça País de publicação: Estados Unidos